Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | EXECUTIVE VICE PRESIDENT | February 27, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 27, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 77,126 |
Reported balance
After 2026-02-27 transaction · row 1
1 source rowRow 1 · 2026-02-27 · Tax withholding · Disposed 4,997 · Balance 77,126 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2026 Filed Mar 4, 2026 01:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,997 | $116.26 | $580,951.22 |
DisclosureSEC source: 0001772286-26-000004 · form4-03042026_010323.xml · nonDerivative · entry 1 Scoggins Christopher J · CIK 0001772286 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,126 Read SEC document |
| February 24, 2026 Filed Feb 27, 2026 00:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 76,273 | $0.00 Strike: $114.60 | $0.00 |
DisclosureSEC source: 0001772286-26-000002 · form4-02272026_120215.xml · derivative · entry 2 Scoggins Christopher J · CIK 0001772286 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,273 Underlying: Common Shares · 76,273 shares Expires 2036-02-23 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 25,424 on February 24, 2027, 25,424 on February 24, 2028, and 25,425 on February 24, 2029. Read SEC document |
| February 24, 2026 Filed Feb 27, 2026 00:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 18,502 | $0.00 | $0.00 |
DisclosureSEC source: 0001772286-26-000002 · form4-02272026_120215.xml · nonDerivative · entry 1 Scoggins Christopher J · CIK 0001772286 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,123 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 21:37 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,223 | $119.84 | $146,564.32 |
DisclosureSEC source: 0001415889-21-001833 · form4-04022021_020404.xml · nonDerivative · entry 1 Scoggins Christopher J · CIK 0001772286 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,121 Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 00:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,846 | $121.58 | $589,176.68 |
DisclosureSEC source: 0001415889-21-001213 · form4-03022021_040334.xml · nonDerivative · entry 1 Scoggins Christopher J · CIK 0001772286 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,344 Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 63,991 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000900 · form4-02232021_040210.xml · derivative · entry 2 Scoggins Christopher J · CIK 0001772286 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,991 Underlying: Common Shares · 63,991 shares Expires 2031-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,330 on February 19, 2022, 21,330 on February 19, 2023, and 21,331 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 12,484 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000900 · form4-02232021_040210.xml · nonDerivative · entry 1 Scoggins Christopher J · CIK 0001772286 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,190 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-21-000528 · form4-02032021_040225.xml · derivative · entry 5 Scoggins Christopher J · CIK 0001772286 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 15,000 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 30,000 | $0.00 Strike: $48.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000528 · form4-02032021_040225.xml · derivative · entry 4 Scoggins Christopher J · CIK 0001772286 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,226 Underlying: Common Shares · 30,000 shares Expires 2025-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 45,000 | $123.24 | $5,545,800.00 |
DisclosureSEC source: 0001415889-21-000528 · form4-02032021_040225.xml · nonDerivative · entry 3 Scoggins Christopher J · CIK 0001772286 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,706 Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 15,000 | $38.40 | $576,000.00 |
DisclosureSEC source: 0001415889-21-000528 · form4-02032021_040225.xml · nonDerivative · entry 2 Scoggins Christopher J · CIK 0001772286 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 30,000 | $48.04 | $1,441,200.00 |
DisclosureSEC source: 0001415889-21-000528 · form4-02032021_040225.xml · nonDerivative · entry 1 Scoggins Christopher J · CIK 0001772286 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 414 | $96.10 | $39,785.40 |
DisclosureSEC source: 0001179110-20-005069 · edgar.xml · nonDerivative · entry 1 Scoggins Christopher J · CIK 0001772286 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,706 Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,048 | $78.91 | $82,697.68 |
DisclosureSEC source: 0001179110-20-004686 · edgar.xml · nonDerivative · entry 1 Scoggins Christopher J · CIK 0001772286 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,120 Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 22:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,240 | $77.89 | $96,583.60 |
DisclosureSEC source: 0001179110-20-002894 · edgar.xml · nonDerivative · entry 2 Scoggins Christopher J · CIK 0001772286 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,168 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,420 | $79.19 | $191,639.80 |
DisclosureSEC source: 0001179110-20-002894 · edgar.xml · nonDerivative · entry 1 Scoggins Christopher J · CIK 0001772286 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,408 Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 68,578 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002261 · edgar.xml · derivative · entry 2 Scoggins Christopher J · CIK 0001772286 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,578 Underlying: Common shares · 68,578 shares Expires 2030-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 22,859 on February 21, 2021, 22,859 on February 21, 2022, and 22,860 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002261 · edgar.xml · nonDerivative · entry 1 Scoggins Christopher J · CIK 0001772286 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,828 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 43,388 | $79.98 Strike: $79.98 | $3,470,172.24 |
DisclosureSEC source: 0001179110-19-004719 · edgar.xml · derivative · entry 2 Scoggins Christopher J · CIK 0001772286 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,388 Underlying: Common shares · 43,388 shares Expires 2029-03-31 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 14,462 on April 1, 2020, 14,463 on April 1, 2021, and 14,463 on April 1, 2022. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 8,278 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-004719 · edgar.xml · nonDerivative · entry 1 Scoggins Christopher J · CIK 0001772286 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,578 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.